NYK-1001 (Nyken Therapeutics)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameNYK-1001 (Nyken Therapeutics)
Drug Alias NameNK-1001NNYK-1001NYK-1001
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHeat-shock protein stimulants
TargetsHeat-shock protein
Therapy Area/IndicationsAtrial Fibrillation
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesChaperone Pharma
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesChaperone Pharma
Active IndicationsN/A
Inactive IndicationsAtrial Fibrillation

Other Information

ATC CodeN/A
Related LinksN/A